ArticleAntonie van Leeuwenhoek2025
Antimicrobial potential of a new Streptomyces species isolated from a brazilian tropical coastal shrubland.
Article in Antonie van Leeuwenhoek, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Draft genome ofMicrobiology resource announcements · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advancing microbial bioprospecting is crucial for discovering novel sources of antimicrobial compounds (ACs). Members of the phylum Actinomycetota, particularly the genus Streptomyces, are renowned producers of a wide variety of bioactive metabolites, including several clinically relevant antibiotics. In the present study, 182 Brazilian actinomycete strains were screened for antimicrobial activity against major human pathogens, namely Staphylococcus aureus MRSA BMB9393, Pseudomonas aeruginosa ATCC 9027, Escherichia coli ATCC 11229, Aspergillus niger ATCC 16404, Candida albicans ATCC 10231, and Cryptococcus neoformans T1444. Among these, strain AM6-12 exhibited strong and broad-spectrum inhibitory activity. To optimize its metabolite production, AM6-12 was grown in various media (ISP-1, ISP-2, Mueller-Hinton, and glycerol-peptone broth) under submerged fermentation at 28 °C for 12 days. Supernatants were collected through centrifugation and filtration and tested via disk diffusion with 100, 150, and 200 μL volumes. Inhibition zones were measured after 36 h at 35 °C. Further experiments in ISP-2 medium under varying aeration conditions (180 vs. 210 rpm; different flask volumes) showed improved activity at 180 rpm, notably against MRSA (2.6 cm) and P. aeruginosa (1.25 cm), indicating oxygen availability influences metabolite synthesis. Genomic sequencing revealed a 7.88 Mb genome with a G + C content of 72.0 mol%. The 16S rRNA gene shared 100% identity with Streptomyces malaysiense MUSC 136, but multilocus sequence analysis (MLSA) of 16S rRNA, atpD, gyrB, rpoB, recA, and trpB showed divergence above the species threshold (MLSA distance > 0.007). Additionally, ANI (< 95%) and digital DNA-DNA hybridization (dDDH < 70%) supported its classification as a distinct species. These findings position AM6-12 as a promising novel Streptomyces species for antimicrobial production.
Indexed as
Identifiers
41171483What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.